Silence Therapeutics plc - 8-K Filing

Silence Therapeutics reports Q3 2026 results and announces definitive agreement for acquisition by Merck KGaA (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits (d) Exhibits)

SEC EDGAR ·

Tickers: $SLN

Read the full article at SEC EDGAR

More Regulatory news